Gt Biopharma Stock Alpha and Beta Analysis
| GTBP Stock | USD 3.80 0.17 4.28% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as GT Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in GT Biopharma over a specified time horizon. Remember, high GT Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to GT Biopharma's market risk premium analysis include:
Beta 1.44 | Alpha (0.69) | Risk 6.04 | Sharpe Ratio (0.13) | Expected Return (0.80) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
GTBP |
GT Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. GT Biopharma market risk premium is the additional return an investor will receive from holding GT Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GT Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate GT Biopharma's performance over market.| α | -0.69 | β | 1.44 |
GT Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of GT Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how GT Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.GT Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how GT Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GT Biopharma shares will generate the highest return on investment. By understating and applying GT Biopharma stock market price indicators, traders can identify GT Biopharma position entry and exit signals to maximize returns.
GT Biopharma Return and Market Media
The median price of GT Biopharma for the period between Fri, Jan 19, 2024 and Thu, Apr 18, 2024 is 4.41 with a coefficient of variation of 20.23. The daily time series for the period is distributed with a sample standard deviation of 0.97, arithmetic mean of 4.8, and mean deviation of 0.77. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | GT Biopharma Shares Resume Trading Unlocking New Opportunities for Investors - Best Stocks | 02/05/2024 |
2 | Disposition of 50000 shares by Steven Weldon of GT Biopharma at 0.33 subject to Rule 16b-3 | 03/18/2024 |
3 | GTBP Stock Earnings GT Biopharma Beats EPS for Q4 2023 - InvestorPlace | 03/26/2024 |
About GT Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GTBP or other stocks. Alpha measures the amount that position in GT Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.002371 | 0.002253 | Days Of Inventory On Hand | 61.05 | 86.22 |
GT Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of GT Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GT Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of GT Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of GT Biopharma. Please utilize our Beneish M Score to check the likelihood of GT Biopharma's management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with GT Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out GT Biopharma Backtesting, GT Biopharma Valuation, GT Biopharma Correlation, GT Biopharma Hype Analysis, GT Biopharma Volatility, GT Biopharma History and analyze GT Biopharma Performance. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
GT Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.